Status:
TERMINATED
Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Arrhythmias
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myoca...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Male and female patients, 18 years of age or older, that have experienced an acute ischemic event within 24 hours prior to study entry.
- Patients with a documented history of coronary artery disease or left ventricular dysfunction
- Patients who have experienced an episode of non-sustained ventricular tachycardia within 24 hours of the index ischemic event
- EXCLUSION CRITERIA:
- Patients who have had percutaneous coronary intervention (PCI), thrombolytics, or open-heart surgery within 48 hours prior to study entry, or who require it during test article administration
- Patients who have taken another antiarrhythmic medication (other than a beta blocker) within 5 half-lives of the start of test article
- Patients who have a history of torsades de pointes, long QT syndrome, QTc \> 0.50
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00124891
Start Date
June 1 2005
End Date
November 1 2006
Last Update
May 3 2022
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Merced, California, United States, 95340
2
Melbourne, Florida, United States, 32901
3
Orlando, Florida, United States, 32803
4
Peoria, Illinois, United States, 61606